Clinical Trial Update: An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation [Phase 2]

View source ↗

Summary

An update on a Phase 2 exploratory trial of afatinib for advanced cancers harboring EGFR, HER2, or HER3 mutations. The trial status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Cancer
• Her3-mutant Cancer
• Mutant Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation | Phase 2 | Status: UNKNOWN